Revenue

Following a debt-for-equity swap, Aventiv Technologies appoints new leadership. Can they navigate calls for reform while delivering returns in a high-stakes market?

Research Frontiers' Q2 call is more than numbers; it’s a window into the multi-billion dollar smart glass market and a unique IP-driven business model.

Northrop Grumman's landmark $3B agreements signal a massive pivot in U.S. defense strategy, accelerating missile production to meet urgent global demand.

The EdTech firm's demand-led move into AI compute is bold, but a complex financial picture and hardware risks create a high-wire act for investors.

Powerus just landed a major Air Force contract, but the real story is its pending merger with a golf course operator. We dissect the risks and rewards of this unorthodox deal.

A pivotal CMS ruling grants Carlsmed's AI-driven spinal implants a dedicated payment code, unlocking market access and signaling a new era for med-tech.

The Oncology Institute's transformation into Starling Oncology signals a strategic pivot to solve the cancer cost crisis through a tech-enabled, coordinated model.

Cohen & Company's Q2 results showcase its mastery of the resurgent SPAC market. With revenue soaring to $69.5M and major deals inked, the boutique firm proves that specialized expertise can deliver outsized returns.

As Sonida Senior Living prepares its Q2 results, investors are watching closely. Can the operator prove its massive merger is paying off amidst industry-wide cost pressures?

A new defense tech player just landed a major Air Force deal. We go beyond the headlines to reveal the financial machinery and strategic plays driving it.

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

Riding a wave of strong Q2 results, Supernus announces a merger of equals with Indivior, set to create a new, scaled player in CNS and addiction medicine.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

As DarioHealth prepares its Q2 results, investors are watching closely. Can its disciplined cost-cutting and AI-powered platform deliver on the promise of profitability?

Gaming giant Flutter Entertainment has abandoned the London Stock Exchange for New York. It's more than a listing change; it's a strategic realignment.

Finnish conglomerate Aspo Plc is demerging into two listed firms, ESL Shipping and Telko Group, betting that strategic focus will unlock significant value.

A class-action suit accuses Bloom Energy of hiding its reliance on Chinese scandium, putting a spotlight on geopolitical risk amid record-breaking growth.

TWC Enterprises reported lower Q2 earnings, but the real story isn't the 9% drop in golf rounds. It's the company's growing reliance on volatile real estate and stock market gains.

A major property sale in Pärnu falls apart, leaving Nordic Fibreboard with a strategic void. We explore the risks of 'conditions precedent' and what this means for the company.